These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12798637)

  • 1. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials.
    Gilbert PB; Chiu YL; Allen M; Lawrence DN; Chapdu C; Israel H; Holman D; Keefer MC; Wolff M; Frey SE;
    Vaccine; 2003 Jun; 21(21-22):2933-47. PubMed ID: 12798637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group.
    Keefer MC; Wolff M; Gorse GJ; Graham BS; Corey L; Clements-Mann ML; Verani-Ketter N; Erb S; Smith CM; Belshe RB; Wagner LJ; McElrath MJ; Schwartz DH; Fast P
    AIDS Res Hum Retroviruses; 1997 Sep; 13(14):1163-77. PubMed ID: 9310283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety profile of HIV vaccination: first 1000 volunteers of AIDS vaccine evaluation group. NIAID AIDS Vaccine Clinical Trials Network.
    Keefer MC; Belshe R; Graham B; McElrath J; Clements ML; Sposto R; Fast P
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S139-40. PubMed ID: 7865288
    [No Abstract]   [Full Text] [Related]  

  • 4. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.
    Belshe RB; Gorse GJ; Mulligan MJ; Evans TG; Keefer MC; Excler JL; Duliege AM; Tartaglia J; Cox WI; McNamara J; Hwang KL; Bradney A; Montefiori D; Weinhold KJ
    AIDS; 1998 Dec; 12(18):2407-15. PubMed ID: 9875578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.
    Baden LR; Walsh SR; Seaman MS; Cohen YZ; Johnson JA; Licona JH; Filter RD; Kleinjan JA; Gothing JA; Jennings J; Peter L; Nkolola J; Abbink P; Borducchi EN; Kirilova M; Stephenson KE; Pegu P; Eller MA; Trinh HV; Rao M; Ake JA; Sarnecki M; Nijs S; Callewaert K; Schuitemaker H; Hendriks J; Pau MG; Tomaka F; Korber BT; Alter G; Dolin R; Earl PL; Moss B; Michael NL; Robb ML; Barouch DH;
    J Infect Dis; 2018 Jul; 218(4):633-644. PubMed ID: 29669026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002.
    Djomand G; Katzman J; di Tommaso D; Hudgens MG; Counts GW; Koblin BA; Sullivan PS
    Public Health Rep; 2005; 120(5):543-8. PubMed ID: 16224987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety profile of recombinant canarypox HIV vaccines.
    de Bruyn G; Rossini AJ; Chiu YL; Holman D; Elizaga ML; Frey SE; Burke D; Evans TG; Corey L; Keefer MC
    Vaccine; 2004 Jan; 22(5-6):704-13. PubMed ID: 14741163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.
    Clements-Mann ML; Weinhold K; Matthews TJ; Graham BS; Gorse GJ; Keefer MC; McElrath MJ; Hsieh RH; Mestecky J; Zolla-Pazner S; Mascola J; Schwartz D; Siliciano R; Corey L; Wright PF; Belshe R; Dolin R; Jackson S; Xu S; Fast P; Walker MC; Stablein D; Excler JL; Tartaglia J; Paoletti E
    J Infect Dis; 1998 May; 177(5):1230-46. PubMed ID: 9593008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network.
    Belshe RB; Clements ML; Dolin R; Graham BS; McElrath J; Gorse GJ; Schwartz D; Keefer MC; Wright P; Corey L
    J Infect Dis; 1993 Dec; 168(6):1387-95. PubMed ID: 8245523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients.
    Ackers ML; Parekh B; Evans TG; Berman P; Phillips S; Allen M; McDougal JS
    J Infect Dis; 2003 Mar; 187(6):879-86. PubMed ID: 12660933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
    Wright PF; Mestecky J; McElrath MJ; Keefer MC; Gorse GJ; Goepfert PA; Moldoveanu Z; Schwartz D; Spearman PW; El Habib R; Spring MD; Zhu Y; Smith C; Flores J; Weinhold KJ;
    J Infect Dis; 2004 Apr; 189(7):1221-31. PubMed ID: 15031791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers.
    Ramanathan VD; Kumar M; Mahalingam J; Sathyamoorthy P; Narayanan PR; Solomon S; Panicali D; Chakrabarty S; Cox J; Sayeed E; Ackland J; Verlinde C; Vooijs D; Loughran K; Barin B; Lombardo A; Gilmour J; Stevens G; Smith MS; Tarragona-Fiol T; Hayes P; Kochhar S; Excler JL; Fast P
    AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1107-16. PubMed ID: 19943789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The human immunodeficiency virus preventive vaccine research at the French National Agency for acquired immunodeficiency syndrome research.
    Fischer E; Rieux V; Guillet JG; Kazatchkine M
    Mem Inst Oswaldo Cruz; 2005 Feb; 100(1):79-84. PubMed ID: 15867969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    Gorse GJ; Corey L; Patel GB; Mandava M; Hsieh RH; Matthews TJ; Walker MC; McElrath MJ; Berman PW; Eibl MM; Belshe RB
    AIDS Res Hum Retroviruses; 1999 Jan; 15(2):115-32. PubMed ID: 10029244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group.
    Graham BS; Keefer MC; McElrath MJ; Gorse GJ; Schwartz DH; Weinhold K; Matthews TJ; Esterlitz JR; Sinangil F; Fast PE
    Ann Intern Med; 1996 Aug; 125(4):270-9. PubMed ID: 8678389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. NIAID AIDS Vaccine Clinical Trials Network.
    Gorse GJ; Frey SE; Patel G; Newman FK; Belshe RB
    Vaccine; 1994 Aug; 12(10):912-8. PubMed ID: 7975833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees.
    Lockey TD; Slobod KS; Caver TE; D'Costa S; Owens RJ; McClure HM; Compans RW; Hurwitz JL
    Immunol Res; 2000; 21(1):7-21. PubMed ID: 10803879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults.
    Mulligan MJ; Russell ND; Celum C; Kahn J; Noonan E; Montefiori DC; Ferrari G; Weinhold KJ; Smith JM; Amara RR; Robinson HL;
    AIDS Res Hum Retroviruses; 2006 Jul; 22(7):678-83. PubMed ID: 16831092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International clinical trials of HIV vaccines: II. phase I trial of an HIV-1 synthetic peptide vaccine evaluating an accelerated immunization schedule in Yunnan, China.
    Li D; Forrest BD; Li Z; Xue P; Hanson CV; Duan S; Cheng H; Li M; Wang CY; Koff WC
    Asian Pac J Allergy Immunol; 1997 Jun; 15(2):105-13. PubMed ID: 9346275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
    Adis International Ltd
    Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.